StockPulse is a software subscription service that translates and summarizes U.S. stock filings and news into alerts. It is not an investment advisory, brokerage, or discretionary management service.

All information provided (filing summaries, price data, keywords, etc.) is processed from public sources for reference only and is not a recommendation to buy or sell any security. Investment decisions and their outcomes are the sole responsibility of the user.

노마드랩 주식회사 · 대표 황승준 · 사업자등록번호 588-81-01342

부산광역시 해운대구 센텀중앙로 55, 9층 7호(우동)

통신판매업 제2026-부산해운대-0983호 · 문의  

고객문의 070-4268-1176

App Store▶ Google Play
GuideFAQWeeklyTerms of ServicePrivacy PolicyPayment & Refund Policy

StockPulse · 스탁펄스(스톡펄스) — 미국주식 공시·뉴스 실시간 알림

© 2026 노마드랩 주식회사. All rights reserved.

StockPulseStockPulseFeedReportMacro·SectorsCommunityAlertsMy
Theme
FeedReportMacro·SectorsCommunityAlertsMy
RTSNRetension Pharmaceuticals, Inc.
stockpulse.co.kr
Nasdaq
$14.43▲ 0.00%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
At a glance🔒 At-a-glance is MAX onlySee plans

Chart

Filings & news by date

Hover (PC) or tap (mobile) a candle to see that day only

🔒 Members only
Live tape🔒 Live tape is MAX onlySee plans

Filings

17
  • 2d agoAfter-hours26.10.23 08:34
    4Ownership#●●●

    Retension Pharmaceuticals, Inc.

    Insider Eric L. Keller of Retension Pharmaceuticals, Inc. reported a change in beneficial ownership of securities on October 22, 2026. This filing formalizes the insider's equity transaction via Form 4.…more

    $14.43+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    View filingShare
  • 2d agoPre-market26.10.23 08:33filed
    8-KKey event

    Retension Pharmaceuticals, Inc.

    Retension Pharmaceuticals has appointed Robert Wong as the new Chief Accounting Officer, effective November 2, 2026. The new CAO will receive an annual base salary of $360,000, a $20,000 sign-on bonus, and a stock option grant for 25,000 shares.…more

    $14.43+0.00%vs prev close
    View filingShare
  • 10.16After-hours26.10.17 06:41
    3Ownership

    Retension Pharmaceuticals, Inc.

    B Group, Inc. has filed a Form 3 initial statement of beneficial ownership regarding its stake in Retension Pharmaceuticals, Inc. The filing discloses the ownership position as of October 13, 2026.…more

    $14.43+0.00%vs prev close
    View filingShare

16 more filings

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →

News

GlobeNewswire

No news collected yet. New articles will appear here.